Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
American Bar Association 2025 Asia-Pacific Conference
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2025
Speaking Engagement
Antitrust
Noerr Competition Day 2025
Speaking Engagement
Antitrust
NBA Commercial Law Section 38th Annual Corporate Counsel Conference
Sponsorship
Antitrust
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
The 32nd Annual Marketing Partner Forum
Event
SABA North America Corporate Counsel Retreat 2025
Sponsorship
Antitrust
Working the Headline-Grabbing Antitrust Cases as a Junior Associate with Axinn: Google Ad Tech
Speaking Engagement
Axinn Participates in Diversity Lab’s Counsel Spotlight
Diversity, Equity & Inclusion
USITC Commissioner Series: Commissioner Schmidtlein is Stepping Down, Which Could Lead to More Tailored Exclusion Orders
Axinn Viewpoints
Intellectual Property